DIAGNOSTIC_TEST
18F/68Ga-Exendin 4
Each subject receive a single intravenous injection of 68Ga/18F-Exendin 4, and undergo PET/CT imaging within the specificed time.
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
Status
Recruiting
Phase
Not applicable
Enrollment
500
Locations
1
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
To evaluate the potential usefulness of 68Ga/18F-Exendin 4 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.
Full detailed description
Subjects with various GLP1-R-related disease patients underwent 68Ga/18F-Exendin 4 PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga/18F-Exendin 4 PET/CT were calculated.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Dec 10, 2024
Study start
Feb 1, 2019
Primary completion
Nov 1, 2027
Study completion
Nov 1, 2027
Results posted
Not reported
Registry updated
Feb 11, 2025
Outcomes
What the study measures.
Primary outcomes
Standardized uptake value (SUV)
Time frame · 30 days
Standardized uptake value (SUV) of Exendin 4 for each target lesion of subject or suspected primary tumor or/and metastasis
Secondary outcomes
Diagnostic efficacy
Time frame · 30 days
The sensitivity, specificity and accuracy of Exendin 4 PET/CT were calculated.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Study locations
1 registered sites.
China. Showing up to 24 locations stored in the fast local snapshot.
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Publications
Results and literature.
Related trials
More studies on Exenatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Johns Hopkins University · Multiple Sclerosis
Phase 2
Recruiting
120
2026-07
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
AstraZeneca · Pancreatic Cancer
Not applicable
Recruiting
24,000
2026-06
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
Chinese University of Hong Kong · Cerebral Small Vessel Disease
Phase 2
Recruiting
110
2026-06
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
University Hospital, Bordeaux · Craniopharyngiomas · Hypothalamic Obesity
Phase 3
Completed
42
2026-05
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital · Cardiovascular Events · Type2 Diabetes
Not applicable
Active, not recruiting
781,430
2026-05
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
Assistance Publique Hopitaux De Marseille · Obesity · Diabetes
Phase 3
Completed
44
2026-05
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease
University College, London · Parkinson's Disease
Phase 3
Completed
194
2026-05
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.